According to Ben et al., the hypermethylation of HOXA9 was associated with worse progression free and overall survival among advanced-stage NSCLC patients undergoing PD-1/PD-L1 inhibitor therapy [22]. This evidence concerns the gene HOXA9 and non-small cell lung carcinoma.